Coronary Heart Disease (CHD)
- In patients with coronary heart disease and
hypercholesterolemia, simvastatin is indicated to:
- Reduce the risk of total mortality by reducing coronary death.
- Reduce the risk of non-fatal myocardial infarction.
- Reduce the risk for undergoing myocardial revascularization
- Reduce the risk of stroke or transient ischemic attack.
- Simvastatin is indicated as an adjunct to diet to reduce
elevated total-C, LDL-C, Apo B, and TG levels, and to increase
HDL-C in patients with primary hypercholesterolemia
(heterozygous familial and nonfamilial) and mixed dyslipidemia.
- Simvastatin is also indicated to reduce total-C and LDL-C in
patients with homozygous familial hypercholesterolemia as an
adjunct to other lipid-lowering treatments.